RT @uptoTate: CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxS

Social Author Image
https://pbs.twimg.com/profile_images/847812732007133184/hIbnEHt3.jpg
Tweet Author
uptoTate
Social Author Name
Dr. Rachel Tate
Tweet Content
CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc
Links
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control… http://ow.ly/vp7150LyZMv
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.